Description: Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-103, a glucagon-like peptide-1 mimetic to treat type 2 diabetes; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was founded in 2012 and is headquartered in San Jose, California.
Home Page: www.ranitherapeutics.com
RANI Technical Analysis
2051 Ringwood Avenue
San Jose,
CA
95131
United States
Phone:
408 457 3700
Officers
| Name | Title |
|---|---|
| Mr. Mir A. Imran | Exec. Chairman |
| Mr. Talat Imran | CEO & Director |
| Mr. Svai S. Sanford | Chief Financial Officer |
| Dr. Mir Hashim | Chief Scientific Officer |
| Mr. Eric Groen | Gen. Counsel |
| Ms. Bella Vazquez | VP of HR |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.6693 |
| Price-to-Sales TTM: | 313.1706 |
| IPO Date: | 2021-07-30 |
| Fiscal Year End: | December |
| Full Time Employees: | 114 |